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ABSTRACT: Iridium-catalyzed C-H activation and ortho-hydrogen isotope exchange is an important technology for allowing 
access to labelled organic substrates and aromatic drug molecules, and for the development of further C-H activation processes in 
organic synthesis. The use of [(COD)Ir(NHC)Cl] complexes (NHC = N-heterocyclic carbene) in the ortho-deuteration of primary 
sulfonamides under ambient conditions is reported. This methodology has been applied to the deuteration of a series of substrates, 
including the COX-2 inhibitors Celecoxib and Mavacoxib, demonstrating selective complexation of the primary sulfonamide over a 
competing pyrazole moiety. The observed chemoselectivity can be reversed by employing more encumbered catalyst derivatives of 
the type [(COD)Ir(NHC)(PPh3)]PF6. Computational studies have revealed that, although C-H activation is rate-determining, sub-
strate complexation or subsequent C-H activation can be product-determining depending on the catalyst employed. 
INTRODUCTION 
Within the realm of organic synthesis, ortho-directed aromatic 
C-H activation remains one of the most active current areas of 
research. Indeed, since the pioneering work of Murai and co-
workers some twenty years ago,
1
 transition metal-catalyzed 
approaches to this methodology have evolved to become pre-
dictable and indispensable tools for synthetic chemists.
2
 
One particularly industry-facing facet of C-H functionaliza-
tion is manifested in iridium-catalyzed hydrogen isotope-
exchange (HIE, Scheme 1).
3
 To alter the properties of a drug 
candidate, the medicinal chemist must first have a flexible 
technique with which to study them. Consequently, isotopic 
labelling with heavy hydrogen isotopes (deuterium, D2, or 
tritium, T2) is widely used as a means to monitor the biological 
fate of a potential drug molecule.
4 
Since the pioneering work 
of Heys in 1992,
5
 a range of iridium catalysts have been re-
ported to efficiently deliver the required hydrogen isotope 
ortho to various functional handles,
3 
as well as in the absence 
of any directing group.
6
 In relation to this, work within our 
own laboratory has focused on the development of iridium(I) 
systems bearing mixed phosphine/N-heterocyclic carbene 
(NHC) ligand spheres which, owing to their steric encum-
brance and electron-donating power, rank among the most 
active catalysts commonly used in the field.
3c,7
 
Regardless of the many accomplishments of iridium-based 
HIE, a key challenge for which no general solution has been 
presented is C-H activation adjacent to primary sulfonamides. 
Related to this, the sulfa drugs derived from sulfonamides 
represent a significant milestone in pharmaceutical science, 
and, since their emergence in 1935, have been developed to 
produce various antibiotics, diuretics, hypoglycemic agents, 
and anti-hypertensive treatments.
8 
To our knowledge, primary 
sulfonamide substrates remain largely unexplored in C-H acti-
vation processes in a general sense.
9,10
 Further, only a handful 
Scheme 1. Hydrogen Isotope Exchange Process 
 
of limited examples of ortho-directed deuterium labelling of 
primary sulfonamides have been reported (Figure 1). Through 
independent studies, Hesk,
11
 and later Herbert,
12
 applied com-
PHUFLDOO\ DYDLODEOH &UDEWUHH¶V FDWDO\VW 3,13 to this problem. 
Despite these studies spanning catalyst loadings of 5 to 100 
mol%, respectively, a maximum of only 15% D in 
benzenesulfonamide was achieved in the latter study. More 
successfully, Lockley applied iridium 1,3-dionate, 4, to 
achieve 66% D in 4-methylbenzenesulfonamide, albeit under 
the high temperature of 130 °C and with a relatively elevated 
catalyst loading of 24 mol%.
14
 Perhaps most notably to date, 
Herbert applied the in-situ generated complex, 5, to the label-
ling of benzenesulfonamide, achieving 85% D at room tem-
perature, but with a substantial 52 mol% catalyst loading.
15
 
Based on our related studies in this area, we reasoned that, 
owing to the tetrahedral geometry of the sulfonamide group, 
and the fact that such HIE processes are believed to proceed 
via concerted C-H activation,
7c,16
 a sterically less encumbered 
and more electron-rich ligand sphere would enhance the effi-
ciency of the sulfonamide coordination and subsequent ortho-
deuteration processes. In this light, we hypothesized that our 
catalyst, 6,
7a,17
 would not be an effective mediator of the de-
sired process, due mainly to the overall ligand size. In con-
trast, however, a complex of the class exemplified by 7,
18
 a 
precursor of 6, fits both the steric and electronic ligand pro-





Figure 1. Past and Present Catalysts Applied to the Labelling Primary Sulfonamides. 
In this contribution, we divulge our exploration of an ex-
tended range of chloro carbene iridium complexes and estab-
lish that the resultant species are active catalysts for the C-H 
activation and labelling of primary sulfonamides under mild 
reaction conditions. Additionally, we report our computational 
analysis of the catalyst design and reaction mechanism, which 
establishes the origin of site-selective labelling in the presence 
of multiple coordinating functionalities. 
RESULTS AND DISCUSSION 
Catalyst Discovery and Optimization. We initiated our 
studies by testing the ability of sterically distinct catalysts 6 
and 7 to mediate the ortho-deuteration of 4-
methylbenzenesulfonamide under our standard labelling con-
ditions.
7
 In agreement with our initial hypothesis, the latter 
system delivered far superior deuterium incorporation, and at 
levels currently unprecedented elsewhere in the literature (Ta-
ble 1, Entry 1 vs. 4). In labelling the related substrates, methyl 
phenyl sulfone and N,4-dimethylbenzenesulfonamide, catalyst 
6 remained inactive (Entry 1 vs. 2 and 3) whilst the activity of 
7 fell markedly (Entry 4 vs. 5 and 6).  Thus, catalyst 7 shows 
exploitable chemoselectivity for coordination of primary sul-
fonamides over secondary sulfonamides and sulfones. 
Having identified 7 as a viable catalyst motif for labelling 
primary sulfonamides, we screened analogues of this system, 
varying the steric bulk and electron-releasing capabilities of 
the pendant NHC ligand (Table 2). Using Nolan and 
&DYDOOR¶V Percent Buried Volume (%Vbur)19 and modified 
Tolman Electronic Parameter (TEP)
18,20
 analyses, two infer-
ences can be drawn from this catalyst screen. Firstly, catalytic 
activity is negligible when %Vbur(NHC) falls below 33.0% 
(Table 2, Entries 1 and 2 vs. 3 ± 7). Presumably, this is as a 
result of the necessity for larger ligands in order to encourage 
reductive elimination, releasing the labelled substrate from the 
active catalyst.
 
Secondly, for NHCs of similar size, those bear-
ing more electron-donating substituents increase catalyst ac-
tivity, supporting a more facile C-H activation across the ortho 
C-H bonds of the substrate (for example, Entry 3 vs. 4). Over-
all, complex 16,
21
 the most electron-rich of all complexes test-
ed, warranted further study. The reaction conditions were fur-
ther optimized to assess the potential for labelling primary 
sulfonamides in reduced reaction times, whilst maintaining 
low catalyst loadings and ambient reaction temperature. This 
was achieved using a full factorial design of experiments 
(DoE),
22
 scrutinizing reaction time, catalyst loading, and sol-
vent volume. Pleasingly, inside 11 experiments, we found that 
a small increase in catalyst loading from 5 to 6.5 mol%, em-
ployed under more dilute solvation, permitted a reduction in 
reaction time from 16 h to just 2 h (see ESI). 
Analysis of Primary Sulfonamide Substrate Scope. We 
next examined the general efficacy of this methodology, ap-
plying the optimized reaction conditions to the ortho-
deuteration of various primary sulfonamides (Table 3). For 
the parent substrate, benzenesulfonamide, 8a, an impressive 
and encouraging 95% D-incorporation was achieved. Similar-
ly, para-alkyl and methoxy-benzenesulfonamides, 12 and 8b ± 
8d, gave excellent levels of deuteration, where only the p-tert-
butyl analogue, 8c, labelled below 90% D. This suggests that 




Entry X/R Catalyst % D 
1 Me/NH2 6 12 
2 H/Me 6 9 
3 Me/NHMe 6 7 
4 Me/NH2 7 90 
5 H/Me 7 17 
6 Me/NHMe 7 8 
a 
Conditions: 9 (0.215 mmol), 6 or 7 (5 mol%), D2 (bal-
loon), DCM, 16 h, 25 °C 
  




















26.4 2049.5 2 5 
/16 
34.9 2046.7 96 
2 
  /14 
30.3 2050.3 3 6 
  /17 
35.8 2050.2 93 
3 
/15 
33.0 2050.3 75 7 
/18 
36.1 2050.8 95 
4 
/7 
33.3 2049.6 90      
a 
Values calculated from DFT-derived structures of proposed active catalyst structures. See ESI for full details.
 
 
the steric influence of the NHC ligand on the catalyst is felt 
even by substituent groups at such a remote position relative 
to the ligating center of the substrate. To demonstrate the prac-
ticality of the HIE procedure, deuteration of 12 was repeated 
using a five-fold increase in reaction scale, with only 4% loss 
in catalyst efficiency. On studying para-halogenated sub-
strates, very good deuteration efficiency was achieved for 
fluoro- and bromo-compounds, 8e and 8f, respectively, 
whereas the iodo-derivative, 8g, gave a much lower deuterium 
content. The most likely explanation for these marked differ-
ences lie in the relative insolubility of 8g in DCM. By a simi-
lar argument, a poor 11% D was achieved when labelling the 
simple sulfa drug, Sulfanilamide,
23
 8h, making any rationaliza-
tion based on competitive coordination of the p-amino group 
unclear. The labelling of more challenging ortho-substituted 
sulfonamides was also investigated. Whereas the methyl sub-
stituent in substrate 8i only moderately affected the efficiency 
of the labelling process, introduction of a bromide or 
trifluoromethyl group (8j and 8k, respectively) meant that 
gentle heating to 40 °C was required to achieve acceptable 
levels of deuteration in the remaining ortho-C-H position. In 
such cases, lone pairs on the heteroatoms may impede the 
substrate coordination to the iridium center. 
Finally, a series of primary sulfonamides holding potentially 
two distinct sites of deuteration through the same sulfonamide 
directing group was studied. For meta-substituted 
benzenesulfonamides, 8l ± 8o, labelling was favored at the 
least hindered C-6 position. Most notably, for the largest meta-
substituent, present in 8n, labelling occurred almost exclusive-
ly at the C-6 position. Moving to naphthalene-1-sulfonamide 
8p, despite the potential for labelling via both 5- and 6-
membered metallocycles, deuteration occurred exclusively at 
the former, and is in line with our previous observations.
7 
In 
the isomeric substrate, 8q, no discrimination was observed in 
labelling at positions C-1 and C-3, both proceeding through 5-
membered metallocycles. However, as with substrates 8g and 
8h, 8q suffers from low solubility in DCM, leading to only 
moderate levels of deuteration overall. 
Competition Studies. The true value of any catalyst system 
can be more fully assessed by determining its robustness in the 
face of additives that may act as a catalyst poison.
24
 Thus, we 
were keen to assess not only the activity of catalyst 16 but its 
ability to label primary sulfonamides in the presence of other 
potential directing groups. Table 4 summarizes a series of 
competition experiments where 11 was deuterated under the 
optimized reaction conditions in the presence of an equimolar 
quantity of a given additive. We were encouraged to find that 
only two of eight additives tested hindered the sulfonamide 
labelling process. Evidently, N-heterocyclic directing groups 
(Entries 1 and 2) compete for coordination to iridium, whereas 
carbonyl-based directing groups (Entries 3 ± 7) and the nitro 
functionality (Entry 8) do not compete as readily with 11. 
However, it should be clarified that, due to the relatively small 
size of each substrate, these studies mainly reflect competing 
directing group electronic characteristics. These studies are 
not believed to be representative of the steric impact of having 
the sulfonamide and the competing functionality in the same 
molecule. 
Labeling Primary Sulfonamides in Multifunctional Drug 
Molecules. In a further assessment of the present ortho-
deuteration protocol, we investigated its utility in labelling the 
more complex drug molecules, Celecoxib, 21, and Mavacoxib, 
22, COX-2 inhibitors first commercialized by Pfizer.
25
 Unlike 
the other substrates in this study, Celecoxib possesses two 
  









 Value in paren-
thesis is indicative of large scale reaction employing 1.075 mmol of 11.  
c 
Values indicate level of deuterium incorporation at 40 
°C. 
d
 Ratio estimated by HRMS. 
 
potential sites of labelling via two distinct directing groups: a 
primary sulfonamide and a pyrazole ring. Employing the op-
timized conditions described above, we compared catalysts 6 
and 16 in their ability to mediate the C-H activation and deu-
terium labelling of 21 and 22 (Table 5). Rather unsurprisingly, 
the more encumbered complex 6 showed unquestionable 
chemoselectivity for C-H activation adjacent to the pyrazole 
rather than the sulfonamide (Table 5, Entries 1 and 3). This 
inactivity of 6 toward the sulfonamide moiety is in agreement 
with earlier studies (Table 1, Entry 1). However, to our sur-
prise, employment of catalyst 16 evidenced a complete switch 
in the chemoselectivity of ortho-deuteration in labelling drug 
molecules 21 and 22 (Table 5, Entries 2 and 4). Indeed, these 
results are in direct contrast to that shown in the competition 
study involving 11 and N-phenylpyrazole (Table 4, Entry 1), 
where the pyrazole outcompeted the sulfonamide in coordinat-
ing and reacting at the iridium center of 16. Accordingly, such 
marked results called for a deeper understanding of the cataly-
sis mechanism and, hence, the origin of the contrasting 
chemoselectivity of ortho-deuteration when using sterically 
distinct catalysts to label such multifunctional molecules as 
employed in this study. 
Mechanistic Investigations. Based on the range of studies 
with various HIE catalysts, and on recent experimental and 
computational studies from our own laboratories, there exists 
an escalating body of insight surrounding the proposed mech-
anism for Ir-catalyzed ortho-deuteration processes.
7c,16
 As 
depicted in Scheme 2 for sulfonamides, pre-catalytic Ir(I) 
species, 6 or 16 for example, is activated by hydrogenative 
loss of the cyclooctadiene (COD) ligand, generating the cata-
lytic Ir(III) dideuteride complex, 24, stabilized by solvation or 
agostic interactions.
26
 Displacement of the loosely bound sol-
vent molecules by substrate 25 produces the intermediate, 26, 
where the substrate is bound to iridium via the directing group 
and an agostic interaction from an ortho-C-H bond. Subse-
quent oxidative addition across the proximal C-H bond, along 
with simultaneous reductive elimination of the cis-deuterides, 
affords 27. It is worth noting that the dual redox processes
  
Table 4. Competition Studies to Assess Robustness and Chemoselectivty of Catalyst System
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Me 93 26 
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Me 97 10 
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Me 94 54 7 
 
Me 93 1 
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Me 95 11 8 
 
H 97 4 
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leading to 27 ensure that iridium remains in the 3+ oxidation 





 then brings a deuteride cis to the 
activated substrate in 28, which then undergoes a second dual 
redox process to give the loosely bound sulfonamide in 29, 
which is quickly released to afford 30 and the regenerated 
catalyst, 24. 
Our attempts to probe the reaction mechanism began by 
measuring the kinetic isotope effect (KIE) of the C-H activa-
tion step.
29
 Thus, exposing substrate 12 to the reverse reaction, 
employing H2 in place of D2, revealed a primary KIE value of 
approximately 3.2, indicating that C-H activation of the ortho-
C-H bonds is involved in the rate-limiting step (Scheme 3). 
Indeed, this is similar in value to that obtained from studies of 
HIE with catalyst 6 and deuterated acetophenone, 31,
7c
 sug-
gesting that both reactions proceed via a similar mechanistic 
process. Additionally, we observed no depletion in the activity 
of catalyst 16 in the deuteration of 11 when the reaction was 
run in the presence of Hg(0).
30
 This supports the view that the 
labelling process operates under homogeneous catalysis. 
COMPUTATIONAL STUDIES 
Substrate Binding, Catalyst Design, and Reaction Mecha-
nism. Based on the outcomes accumulated to this stage, we 
followed our experimental studies with a complementary theo-
retical analysis of the operative reaction mechanism.
31
 The 
first task was to strengthen our original hypothesis for the 
catalyst design, aiming to show that catalysts such as 16 (or 7), 
with a relatively small coordination sphere, can bind and react 
with the large sulfonamide directing group more readily than 
encumbered catalysts such as 6. To this end, we assessed the 
sulfonamide binding and C-H activation enthalpies of repre-
sentative catalysts 6 and 16 (cf. processes 24 to 26, and 26 to 
27, Scheme 2). Interestingly, on assessing the substrate bind-
ing energies to the appropriate analogues of 34, we established 
that complexation of benzenesulfonamide, 25, to the activated 
form of 6 is more exothermic than to the equivalent activated 
form of 16 (34 to 35a, Scheme 4).
32 
However and in contrast, the rate-limiting C-H activation 
process is less endothermic when the smaller catalyst is em-
ployed (35a to 35b, Scheme 4). This is in qualitative agree-
ment with our experimental findings (Table 1, Entries 1 and 
4) and infers that the reduced steric encumbrance of catalyst 
16 relative to 6 is essential for efficient catalytic reactivity 
with sulfonamide substrates. 









1 6 Me 16 95 
2 16 Me 97 11 
3 6 F 7 89 
4 16 F 98 11 
a 
Conditions: 21 or 22 (0.05 mmol), 6 or 16 (6.5 mol%), D2 
(balloon), DCM, 25 °C, 2 h. 
  
Concentrating on catalyst 16, we subsequently calculated the 
full potential energy surface (PES) of the labelling reaction 
with 25. In line with our KIE studies, C-H activation was 
shown to be the most energetically demanding and thus rate- 
limiting step (36 to 37, Figure 2). Furthermore, we calculated 
a theoretical KIE of 3.9 for this step, showing very good 
agreement with the experimental estimate. As with our previ-
ous studies,
7c
 the initial C-H activation step is endergonic.
27
 
Comparatively, hydride fluxionality (37 to 38) is energetically 
neutral on the PES. Finally, the second C-H activation step (38 
to 39) almost mirrors the first, and is exergonic in nature. 
Chemoselectivity and Catalyst Structure. With the above 
insights in place, attention turned to explaining the origins of 
labelling chemoselectivity (Table 5).  Previously, we studied 
the regioselectivity of labelling benzanilide which, through a 
single coordinating group, can undergo HIE through a 5- or a 
6-membered iridacycle.
7
 In that case, a preference to label 
through the smaller 5-membered iridacycle was shown to orig-
inate from energetic differences in the C-H activation step,
7c
 
with the initial binding of the substrate proving to be insignifi-
cant. Conversely, the situation with sulfa-drugs 21 and 22 is 
more complex. There are now two structurally different coor-
dinating groups, both directing ortho-deuteration through a 5-
membered iridacycle. As such, it cannot be assumed that the 
observed labelling selectivity using catalysts 6 and 16 is re-
sultant of the oxidative addition or the initial binding step. A 
detailed study of the overall substrate complexation and C-H 
activation pathways of Celecoxib, 21, with catalysts 6 and 16 
was thus undertaken. 
Firstly, we scrutinized the binding interactions and C-H ac-
tivation of 21 with the larger catalyst, 6 (Figure 3). From the 
appropriate analogue of 34 (Scheme 4), solvated explicitly  
 
 
Scheme 2. Proposed Mechanism for Ir-Catalyzed HIE  
 
Scheme 3. Investigation of Kinetic Isotope Effects  
 
 
with two DCM molecules, subsequent complexation of 21 and 
release of solvent proved entropically favourable and 
enthalpically neutral for substrate binding modes, 40 and 41. 
However, both complexation and subsequent C-H activation 
are significantly lower in energy when proceeding through 40, 
leading to ortho-deuteration via the pyrazole. This is in 
agreement with experimentally observed labelling 
chemoselectivity (Table 5, Entry 1). Additionally, it is im-
portant to note that the energy difference in the binding modes 
¨¨*bind = 13.1 kcal mol-1) is much larger than the energy 
difference in the C-H activation WUDQVLWLRQ VWDWHV ¨¨*trans = 
0.6 kcal mol
-1
). We can therefore infer that the observed pyra-
zole chemoselectivity in labelling 21 with catalyst 6 originates 
from the complexation event more so than the subsequent C-H 
activation process. 
 
Scheme 4. Calculated Energies for Binding of 






We then sought to explore the change in labelling 
chemoselectivity observed upon switching from encumbered 
catalyst, 6, to the smaller catalyst, 16 (Table 5, Entry 2). Simi-
larly to Figure 3, complexation and C-H activation of 21 with 
catalyst 16 were modelled computationally (Figure 4).
33 
Now, 
substrate complexation is calculated to be enthalpically disfa-
voured, presumably in connection with the lower 
electrophilicity of catalyst 16 relative to 6. Nonetheless, there 
is once again a clear energetic bias for complexation and sub-
sequent C-H activation through one directing group: the sul-
fonamide rather than the pyrazole. In this case, discrimination 
between the binding modes 42 and 43 ¨¨*bind = 3.7 kcal mol-
1
) is more similar in magnitude to the energy difference in the 
subsequent C-H activation SDWKZD\V¨¨*trans = 0.7 kcal mol-
1
). Thus, we believe that chemoselective binding and labelling 
adjacent to the sulfonamide using the chloro/carbene catalysts 
is dictated by the combined influence of substrate binding and 
C-H activation transition state energies.
34
 The selective bind-
ing of the sulfonamide functionality in 21 by catalyst 16 is 
worthy of further discussion. Whereas benzenesulfonamide, 
25, was predicted to bind to 16 via the nitrogen lone pair, 
Celecoxib, 21, binds preferentially through an oxygen lone 
pair, supplemented by a hydrogen bond between the amino 
group of the substrate and the chloride ligand of the catalyst. 
This highlights the flexible nature of the sulfonamide directing 
group, with the nitrogen or oxygen groups able to actively 
participate, depending on the structure of the substrate and 
catalyst. 
CONCLUSION 
In summary, we have established a general and selective 
method for C-H activation ortho to primary sulfonamides by 
applying complexes of the type [(COD)Ir(NHC)Cl], leading to 
highly effective levels of hydrogen-deuterium exchange. 
Sterically large and electron-rich NHC ligands were necessary 
for efficient catalysis, with complex 16 being the most active 
of seven such species tested. Interestingly, our most common-
ly used isotope exchange catalyst, 6, a more encumbered de-
rivative of 16, was shown to be inactive towards sulfonamides. 
Having then optimized the reaction time, catalyst loading, and 
dilution, through DoE techniques, a series of sulfonamides 
were deuterated under mild conditions using 16. Specifically, 
alkyl, halogen, methoxy, trifluoromethyl, and naphthyl-
substituted aryl sulfonamide derivatives were tolerated, with 
ortho-, meta-, and para-substitution having also been explored 
in the substrate scope. A notable limitation of this methodolo-
gy lies in the poor solubility (and hence %D in the labelling 
reaction) of several substrates (8g, 8h, and 8q). Supplementary 
studies are currently ongoing within our laboratory to find 
reaction media alternative to DCM. 
In further exploration of the reaction scope, competition 
studies revealed the ability of catalyst 16 to selectively label 
sulfonamide, 11, in the face of ketone, ester, nitro, and various 
amide directing groups. Only the N-heterocycles, 1-
phenylpyrazole and 2-phenylpyridine, were able to compete 
with 11 to reverse the chemoselectivity of labelling in these 
 
 
Figure 2. Potential Energy Surface (PES) for ortho-deuteration of benzenesulfonamide with catalyst 16, scaled according to free 
energy, Grel. Details of the theoretical KIE calculation can be found in the ESI. 
  
 
Figure 3. PES for the complexation and C-H activation of 
Celecoxib, 21, with catalyst 6. Energies are relative to the 




Figure 4. PES for the complexation and C-H activation of 
Celecoxib, 21, with catalyst 16. Energies are relative to the 
appropriate DCM solvated analogue of 34. 
 
studies. We have also successfully applied catalyst 16 to the 
ortho-deuteration of multifunctional sulfa-drugs Celecoxib, 
21, and Mavacoxib, 22. Interestingly, catalyst 16 showed ex-
cellent levels of chemoselectivity towards the sulfonamide 
over the pyrazole directing group and in a manner completely 
contrary to our competition studies employing simpler sub-
strates. Further still, we have demonstrated the ability to 
switch the chemoselectivity in labelling 21 and 22 by employ-
ing catalyst 6 in place of 16. This highlights a necessity to 
consider more intimately the interactions between individual 
catalyst and substrate species.
35
 
Finally, with a combination of experimental KIE studies and 
computational mechanistic analyses, we have revealed that the 
ortho-deuteration of primary sulfonamides with catalyst 16 
proceeds similarly to analogous HIE processes employing 
catalyst 6.
7c
 Further, we have analysed the complexation 
modes and C-H activation pathways associated with labelling 
Celecoxib, 21 using catalysts 6 and 16. As a result, we can 
now propose that the pyrazole chemoselectivity of catalyst 6 is 
driven by the substrate complexation event, whereas the sul-
fonamide selectivity imparted by catalyst 16 is influenced by 
the energetics of both complexation and subsequent C-H acti-
vation. This, once again, emphasizes the importance of con-
sidering the interactions of catalyst and substrate in acute de-
tail aligned to the overall C-H activation process, as the ob-
served activities and chemoselectivities may be as a result of 
more than one contributing factor. 
Work is on-going within our laboratories to extend the ap-
plication of these emerging iridium catalyst species to a more 
expansive array of substrate classes, including sulfonamide-
based molecular architectures, as well as to alternative C-H 
activation processes in a wider sense. 
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